Alarkawi D, Ali MS, Bliuc D, et al. - In this population-based cohort study, researchers explored the connection between oral bisphosphonates (oBP) and all-cause mortality in G3B-5D CKD. The sample consisted of all individuals with an eGFR < 45/ml/min/1.73m² aged 40+ years from the UK Clinical Practice Research Datalink (CPRD) and the Catalan Information System for Research in Primary Care. Previous and current users of other anti-osteoporosis drugs have been eliminated. In the CPRD, of 19,351 oBP users and 210,954 non-oBP users, 5,234 and 85,105 deaths have been documented over 45,690 and 915,867 person-years of follow-up, respectively. Compared with non-oBP users, oBP users had 8% lower mortality risk. This became non-significant following PS trimming. Findings suggested no association of oBP with increased mortality amongst individuals with moderate-severe CKD. However, further investigations are required on other impacts of oBP in CKD individuals.